Peptide clinics — typically branded as "wellness clinics," "longevity clinics," or "men's health clinics" — have expanded dramatically across the United States over the past five years. They offer medically supervised peptide protocols, typically via telemedicine, for everything from injury recovery to weight loss to cognitive enhancement. Here is how the model actually works, what oversight is and isn't in place, and the questions you should be asking before you hand over a credit card.

The Basic Business Model

Most peptide clinics operate a variation of the same model:

  1. Online intake form (health history, goals, symptoms)
  2. Brief telemedicine consultation with a physician or NP (typically 15-30 minutes)
  3. Prescription issued for one or more peptides from a compounding pharmacy
  4. Peptides shipped directly to patient, often with reconstitution supplies
  5. Ongoing subscription for refills and quarterly follow-up consultations

The economics favor recurring revenue. Initial consultation fees range from $150-400. Monthly peptide costs range from $200-800 depending on protocols. The subscription model creates strong incentives to keep patients on protocols regardless of whether outcomes justify continuation.

What "Medical Supervision" Actually Means

The phrase "medically supervised" is doing a lot of work in peptide clinic marketing. What it generally means in practice:

What it means: A licensed physician or nurse practitioner has reviewed your health history, determined you don't have obvious contraindications, and issued a prescription. This creates a legal pathway for compounding pharmacies to produce and ship the peptides. It also shifts liability from the patient to the prescribing provider.

What it doesn't mean: That the prescribing physician has deep expertise in peptide pharmacology. That there is ongoing monitoring of your blood work or biomarkers. That someone is tracking adverse events. That the protocol being recommended is evidence-based for your specific condition. Most peptide clinic physicians are general practitioners or urgent care doctors who have completed a brief certification course in "hormone optimization" or "regenerative medicine."

The telemedicine format limits what is possible. A 20-minute video call cannot replicate the diagnostic rigor of an in-person evaluation. For most patients, the "consultation" functions primarily as a regulatory formality required to access the prescription rather than a substantive clinical encounter.

The Compounding Pharmacy Layer

Peptides prescribed through clinics are typically compounded — that is, manufactured by a licensed compounding pharmacy that mixes pharmaceutical-grade ingredients to fill the specific prescription. This is the key distinction between clinic-prescribed peptides and gray-market research chemicals.

Compounding pharmacies are regulated — but the regulatory picture is more complicated than clinic marketing implies:

  • 503A compounding pharmacies (traditional, patient-specific compounding) operate under state pharmacy board oversight with some FDA involvement. Quality standards vary significantly by state.
  • 503B outsourcing facilities are federally regulated by the FDA under stricter GMP (Good Manufacturing Practice) standards. Peptides from 503B facilities are closer to pharmaceutical-grade quality control.
  • Most peptide clinics do not specify which type of facility they use, and many patients don't know to ask.

The FDA has taken increasingly aggressive action against compounded peptides since 2023. BPC-157, TB-500, and several GHRPs have been added to the FDA's "difficult-to-compound" list, which restricts their availability from compounding pharmacies. Some clinics have shifted to overseas pharmacies or alternative sourcing as a result — which moves the product outside even the compounding pharmacy regulatory framework.

What the Clinic Is Actually Selling

Peptide clinics sell three things, bundled together:

1. Regulatory access. The prescription makes legally obtained, higher-quality peptides possible. This is real value — pharmaceutical-grade vs. gray-market sourcing is a meaningful quality and safety difference.

2. Medical cover. A physician has signed off. This reduces psychological risk for the patient and shifts liability. It does not reduce biological risk.

3. A narrative. Most peptide clinic marketing is built around compelling outcome stories — recovery timelines, before/after testimonials, protocol "transformations." These are powerful marketing tools and essentially no evidence for efficacy. Anecdotes from people who paid for a service and want to justify that payment are not clinical outcomes data. For any specific claim they make — like AOD-9604 burning fat without diet or exercise — the evidence rarely matches the pitch.

The Oversight Gap

The most important thing peptide clinics won't tell you: there is no systematic adverse event tracking for these protocols. When something goes wrong — and things do go wrong, even if the frequency is unknown — there is no regulatory infrastructure collecting that data.

FDA MedWatch is designed for approved pharmaceutical products. Adverse events from compounded peptides prescribed by telemedicine clinics exist in a data black hole. The prescribing physician may receive a complaint. The compounding pharmacy may hear nothing. The clinic's marketing continues unchanged.

This is not unique to peptide clinics — it applies to compounded medicine broadly. But it's particularly relevant here because the compounds being used have limited clinical trial data to begin with. We are not monitoring outcomes from a well-characterized pharmaceutical. We are monitoring outcomes from compounds that haven't completed efficacy trials, at doses reverse-engineered from animal data, in an unsupervised population with no adverse event reporting infrastructure. The TB-500 regeneration claim and similar promises haven't been validated in this real-world clinical context.

Questions to Ask Before Signing Up

If you're evaluating a peptide clinic, these are the questions that separate thoughtful providers from marketing operations:

  • What compounding pharmacy do you use, and is it 503A or 503B? A clinic that can't answer this question quickly is not running a tight operation.
  • What baseline labs will you order before starting? Any protocol affecting the endocrine system (GHRPs, sermorelin) should involve baseline IGF-1, glucose tolerance, and relevant panels. If no labs are mentioned, the "supervision" is minimal.
  • What specific outcome are you treating, and what evidence supports this peptide for that outcome in humans? A good physician should be able to cite specific clinical evidence. "Works great for my other patients" is not clinical evidence.
  • What are the monitoring checkpoints? Quarterly consultations should include labs, not just symptom check-ins.
  • What is your protocol if I have an adverse reaction? Emergency contact, clear escalation path, and documentation protocols should exist. Most clinics have none of this formalized.
  • What is your cancellation policy? Subscription models with punishing cancellation terms are a signal about where the clinic's priorities are.

The Honest Value Proposition

Peptide clinics occupy a real gap in medicine. People with legitimate recovery goals, persistent injuries, or aging-related concerns often cannot access substantive evaluation through conventional healthcare. A clinic that offers thoughtful, evidence-informed protocols with real oversight is providing genuine value.

The problem is that most peptide clinics are not that. They are subscription businesses that have identified a market willing to pay for compounds with compelling mechanisms and compelling marketing. The "medical supervision" is real in a legal sense and minimal in a clinical sense. The compounds may work — some of the mechanisms are genuine — but the evidence base that would tell you they work for your specific situation, at the doses being prescribed, for the duration being recommended, does not exist.

Before committing to any peptide protocol, score the specific claims being made for your target outcomes. Not the clinic's general framing, but the actual claim: "this peptide will produce this outcome in your situation." That's where the evidence gap is usually most visible.